Table 2.
Univariate analysis in overall patients
| Characteristics | Hazard ratio (95% CI) | P value* |
|---|---|---|
| Age (years)† | 0.981 (0.958-1.004) | 0.106 |
| Sex | 0.937 (0.558-1.576) | 0.807 |
| Etiology of CLD | 0.361 (0.090-1.439) | 0.149 |
| Portal vein thrombosis | 6.716 (4.169-10.819) | < 0.001 |
| Child-Pugh class | 1.264 (0.833-1.918) | 0.270 |
| AJCC Tumor stage | 4.759 (3.410-6.643) | < 0.001 |
| BCLC Tumor stage | 1.532 (1.383-1.698) | < 0.001 |
| Serum AFP† | 1.0000007 (1.0000002-1.0000013) |
0.008 |
| Serum AFP (≥ 400 ng/mL) | 3.666 (2.332-5.762) | < 0.001 |
| Serum PIVKA-II† | 1.000102 (1.00007-1.00012) |
< 0.001 |
| Serum PIVKA-II (≥ 300 mAU/mL) | 8.701 (5.394-14.035) | < 0.001 |
| Platelet count (≤ 130 × 103/μL) | 2.319 (1.454-3.698) | 0.0004 |
| PT (≤ 80%) | 0.737 (0.460-1.179) | 0.203 |
| Albumin (≥ 3.5 g/dl) | 0.790 (0.498-1.252) | 0.316 |
| Total bilirubin (≥ 1.5 mg/dL) | 1.174 (0.287-4.796) | 0.823 |
Values in the column are represented as number of patients (%) or median value (range).
Abbreviation: CLD, chronic liver disease; AFP, alpha-fetoprotein; PIVKA-II, Protein induced by vitamin K absence or antagonist-II; PT, prothrombin time; AST, aspartate aminotransaminase; ALT, alanine aminotransferase.
*P-values for each clinical variable calculated using Cox regression analysis.
†all were used with continuous variables.